Clinical Investigators Review Sutura Next Generation SuperStitch Vessel Closure Device.

FOUNTAIN VALLEY, Calif. -- Sutura(R), Inc.("Sutura(R)"), a California-based medical device company, announced today the completion of the Company's Bi-Annual Clinical Investigators Meeting at its 20,000 square foot facility in Fountain Valley, California. The primary purpose of the meeting was to present Sutura's new 'as simple as 1-2-3 concept' that makes it easier for physicians to deploy the SuperStitch(R) which closes the femoral puncture site using the catheter sheath introducer to access the femoral artery wound.

Attending the Bi-Annual Clinical Investigators Meeting were Sutura's Senior Clinical Advisor, Dr. John Crew, Medical Director of Vascular Research at the San Francisco Heart and Vascular Institute, Dr. Thomas Davis, Consulting Interventional Cardiologist at Park Nicollet Heart Center in Minneapolis, and Dr. Alan Heldman, Director of Interventional Innovation and Research at Johns Hopkins Hospital in Baltimore (http://www.hopkinshospital.org/Faculty/Heart/Heldman.html).

"The response from the clinical investigators was extremely encouraging," said Anthony Nobles, CEO/President of Sutura(R), "The new 'as simple as 1-2-3' handle was designed to reduce the time required to train physicians to operate the SuperStitch(R). We believe the new easy-to-use system accomplishes this and now, with the clinical investigators input, we are ready to commence sales of the product to Cath-Labs across the country."

"The Doctors attending the Clinical Investigators meeting also provided us with some valuable feedback on the sales and marketing plan for the SuperStitch(R)," said Tom Lindsey, Sutura's U.S. Director of Sales and Marketing. They also had an opportunity to use the SuperStitch(R) in our lab, and experience the new system first hand. This immediate feedback from the physicians was an essential step in developing our full-scale product launch to the medical community scheduled to begin in January."

Sutura, Inc. announced November 22, 2004 that it has signed an Agreement and Plan of Merger with Technology Visions Group, Inc. (OTCBB:TVGR) of San Marcos, California. Both Company's are in the process of conducting due diligence and securing the approval of the merger by their shareholders.

About Sutura, Inc.

Sutura(R), Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive vessel closure devices to suture the puncture created in the femoral artery during catheter-based procedures, primarily in the fields of cardiology and radiology. The SuperStitch(R) devices allow physicians to close the femoral puncture site using the catheter sheath introducer to access the femoral artery wound. Sutura believes that its products will allow a physician to more quickly and safely conclude catheter-based procedures and, in addition, allow the patient to become ambulatory sooner than with traditional methods of managing arterial puncture wounds. Sutura has received 510(k) clearance from the FDA to sell its F8 & F6 SuperStitch(R) devices in the United States and has the CE mark permitting sale in Europe. Sutura has also met all of the registration requirements for selling the SuperStitch(R) devices in Australia. Sutura's headquarters are in Fountain Valley, California. "Sutura(R)" and "SuperStitch(R)" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch(R) devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.